aTyr Pharma, Inc.(US:ATYR) Newsfile·2025-11-11 14:50Core Points - A class action securities lawsuit has been filed against aTyr Pharma, Inc. to recover losses for shareholders affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [2][3] - The lawsuit claims that aTyr Pharma made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper off steroid usage [3][4] - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [4][5] Company Impact - Following the announcement of the study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in just one day [5] - The company plans to engage with the FDA to determine the next steps after the disappointing study results [4] Legal Context - Shareholders who suffered losses during the relevant time frame are encouraged to seek recovery, with no cost or obligation to participate in the lawsuit [6] - Levi & Korsinsky LLP, a recognized securities litigation firm, is representing the shareholders in this case, highlighting their extensive experience and success in similar cases [7]